当前位置： SCI文献检索 > HIV CLINICAL TRIALS期刊下所有文献 > Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.

Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.

Abstract：

PURPOSE:The objectives of this study were to determine the prevalence of osteopenia and the factors associated with its presence in HIV-infected patients under highly active antiretroviral therapy (HAART) and to assess the changes of bone mineral density (BMD) in a population followed prospectively. METHOD:BMD was assessed by dual-energy X-ray absorptiometry (DEXA) scans at the lumbar spine and at the femoral neck in 78 HIV-infected patients who had previously received HAART as the first antiretroviral regimen and in 11 antiretroviral-naive HIV-infected patients. BMD measurements were repeated in 70 treated patients who had completed 1 year of follow-up. RESULTS:Thirty-seven (42%) patients showed osteopenia at any localization. The prevalence of osteopenia in PI-naive patients was 23% versus 49% in individuals who had received PI at any moment [p =.001; adjusted odds ratio (95% CI) = 0.11 (0.02-0.48)]. The frequency of osteopenia was significantly higher among men than among women [50% vs. 17%; p =.016; adjusted OR (95% CI) = 12.1 (2.22-66.20)]. The level of plasma albumin was independently associated with osteopenia [adjusted OR (95% CI) per each g/dL of plasma albumin decrease 2.55 (1.18-10)]. In patients in whom a second DEXA was done, no significant changes in BMD were found. CONCLUSION:The prevalence of osteopenia in HIV-infected patients on HAART is high. Loss of BMD is associated with PI therapy, low plasma albumin level, and male sex. Osteopenia does not progress after 1 year of continued HAART.

journal_name

HIV Clin Trials

journal_title

HIV clinical trials

authors

Fernández-Rivera J,García R,Lozano F,Macías J,García-García JA,Mira JA,Corzo JE,Gómez-Mateos J,Rueda A,Sánchez-Burson J,Pineda JA

doi

10.1310/4X0H-UVMJ-BHYW-CPFB

keywords:

subject

Has Abstract

pub_date

2003-09-01 00:00:00

pages

337-46

issue

5

eissn

1528-4336

issn

1945-5771

journal_volume

4

pub_type

杂志文章

相关文献

HIV CLINICAL TRIALS文献大全
  • Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients.

    abstract：:Three HIV individuals with chronic hepatitis C presented with esophageal variceal bleeding. They had mild liver fibrosis and normal liver function tests. All had received didanosine for long periods. Noncirrhotic portal hypertension associated with didanosine may appear in HIV patients without any liver disease or add...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct0906-440

    authors： Vispo E,Maida I,Barreiro P,Moreno V,Soriano V

    更新日期：2008-11-01 00:00:00

  • Randomized, placebo-controlled trial of product R, a peptide-nucleic acid immunomodulator, in the treatment of adults infected with HIV.

    abstract：OBJECTIVE:The efficacy of Product R, a nontoxic peptide-nucleic acid, was tested in 43 HIV-infected adults naïve to antiretroviral therapy. METHOD:Patients were randomized to receive Product R (21 patients) or placebo (22 patients). Dosage was two 1 mL subcutaneous injections daily on days 1-14, followed by 1 mL daily...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1310/N34A-653T-ABF5-8Q1R

    authors： Levett PN,Hirschman SZ,Roach TC,Broome H,Alexander RJ,Fraser HS

    更新日期：2002-07-01 00:00:00

  • Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider.

    abstract：PURPOSE:To investigate the factors that contribute to willingness to participate in HIV clinical trials and to determine the impact of a brief intervention on willingness to participate. METHODS:115 consecutive outpatients receiving HIV primary care participated in this prospective study. Each patient completed a ques...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1002-104

    authors： Volkmann ER,Claiborne D,Currier JS

    更新日期：2009-03-01 00:00:00

  • The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.

    abstract：PURPOSE:To assess the effect of changing antiretroviral therapy in patients initially treated with saquinavir hard gel capsule (hgc). METHOD:A retrospective cohort study comparing the virological and immunological responses in antiretroviral-naïve patients initially treated with a regimen of saquinavir-hgc, zidovudine...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/KED4-8TW3-4ARG-HFC5

    authors： Jensen-Fangel S,Kirk O,Blaxhult A,Gerstoft J,Pedersen C,Black FT,Lundgren JD,Obel N

    更新日期：2001-03-01 00:00:00

  • Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

    abstract：OBJECTIVES:Week 96 efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) was compared to efavirenz (EFV) in subset of 1,096 subjects who received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in pooled data from 2 phase 3 studies. METHODS:ECHO and THRIVE are double...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,随机对照试验

    doi：10.1310/hct1403-81

    authors： Nelson MR,Elion RA,Cohen CJ,Mills A,Hodder SL,Segal-Maurer S,Bloch M,Garner W,Guyer B,Williams S,Chuck S,Vanveggel S,Deckx H,Stevens M

    更新日期：2013-05-01 00:00:00

  • Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

    abstract：BACKGROUND:To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen. METHOD:HIV-1-infected, antiretroviral drug-naïve adults were randomized to either twice-daily nelfinavir and stavudine and once-daily didanosine (regimen A) or...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,随机对照试验

    doi：10.1310/A686-M37Y-J2PT-E9GJ

    authors： Lowe SH,Wensing AM,Hassink EA,ten Kate RW,Richter C,Schreij G,Koopmans PP,Juttmann JR,van der Tweel I,Lange JM,Borleffs JC

    更新日期：2005-09-01 00:00:00

  • Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.

    abstract：PURPOSE:Treatment options for HIV-associated lipodystrophy syndrome (HALS) remain limited. The objective of this randomized open-label study was to compare three emerging therapies, rosiglitazone, pravastatin, and growth hormone alone and together, in men and women with HALS. METHOD:Sixty-four subjects received daily ...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1310/hct0904-254

    authors： Macallan DC,Baldwin C,Mandalia S,Pandol-Kaljevic V,Higgins N,Grundy A,Moyle GJ

    更新日期：2008-07-01 00:00:00

  • A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.

    abstract：BACKGROUND:A safe, effective, easy-to-dose antiretroviral therapy that minimizes hepatic complication risk is essential in optimizing HIV-HCV treatment. Nucleoside-sparing boosted protease inhibitor monotherapy may achieve this goal. METHODS:A prospective, open-label pilot simplification study of once-daily lopinavir/...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/hct1304-179

    authors： Cooper C,la Porte C,Tossonian H,Sampalis J,Ackad N,Conway B

    更新日期：2012-07-01 00:00:00

  • Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.

    abstract：OBJECTIVES:Statins are lipid-lowering drugs that exhibit anti-Inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. DESIGN:To assess the anti-inflammatory effects of statins in HIV-infected patients, because very limited data are av...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1501-1

    authors： Calza L,Vanino E,Salvadori C,Manfredi R,Colangeli V,Cascavilla A,Di Bari MA,Motta R,Viale P

    更新日期：2014-01-01 00:00:00

  • Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain.

    abstract：OBJECTIVE:To determine the prevalence of CCR5-tropic HIV-1 among treatment-experienced patients in Spain. DESIGN:Epidemiologic, cross-sectional, and non-interventional study between January and June 2008 in HIV-1-infected patients in Spain. METHODS:A total of 485 treatment-experienced patients from across Spainand wi...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1006-394

    authors： Moreno,Clotet,Sarría,Ortega,Leal,Rodriguez-Arrondo,Sánchez-de la Rosa,Allegro Study Group.

    更新日期：2009-11-01 00:00:00

  • Serious renal impairment occurs rarely with use of tenofovir DF.

    abstract：PURPOSE:The purpose of this study was to evaluate the short-term effects (up to 6 months) of tenofovir disoproxil fumarate (DF) use on renal function in patients being treated for HIV-1 infection. METHOD:The charts of 447 HIV-1-infected patients who received at least three months of tenofovir DF treatment were reviewe...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,多中心研究

    doi：10.1310/2taj-qpd1-tyae-qak5

    authors： Scott JD,Wolfe PR,Bolan RK,Guyer B

    更新日期：2006-03-01 00:00:00

  • Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.

    abstract：OBJECTIVES:Despite substantial improvements in HIV outcomes with combination antiretroviral therapy (cART), morbidity and mortality remain above population norms. The gut mucosal immune system is not completely restored by cART, and the resultant microbial translocation may contribute to chronic inflammation, inadequat...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1080/15284336.2016.1184827

    authors： Kim CJ,Walmsley SL,Raboud JM,Kovacs C,Coburn B,Rousseau R,Reinhard R,Rosenes R,Kaul R

    更新日期：2016-07-01 00:00:00

  • Sustained efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV-infected patients: a 48-week retrospective multicenter study.

    abstract：BACKGROUND:Nevirapine, a nonnucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the durable suppression of HIV with nevirapine when used along with other nucleosides in HIV-infected patients who are treated in clinical practice n...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,多中心研究

    doi：10.1310/4nb4-1gx6-4xvk-pbgl

    authors： Allan PS,Arumainayagam J,Harindra V,Tobin J,Browning M,Yoganathan K,Wade A,Das S

    更新日期：2003-07-01 00:00:00

  • Missing scheduled visits in the outpatient clinic as a marker of short-term admissions and death.

    abstract：INTRODUCTION:It is not uncommon for patients with HIV infection to miss scheduled visits in outpatient clinics without justifying the failure to appear or reschedule the appointment. Few studies have assessed the impact of inconsistent follow-ups on resource use and disease outcomes in this patient population. OBJECTI...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1305-289

    authors： Colubi MM,Pérez-Elías MJ,Elías L,Pumares M,Muriel A,Zamora AM,Casado JL,Dronda F,López D,Moreno S,SEAD Study Group.

    更新日期：2012-09-01 00:00:00

  • Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls.

    abstract：BACKGROUND:Perinatally acquired HIV-infected (PaHIV) young adults undergo neurodevelopment in the presence of HIV infection and antiretroviral therapy, which may lead to neurocognitive (NC) impairment. Knowledge of NC function in this group is sparse and control data lacking. We compared cerebral function in young adul...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1179/1528433614Z.0000000003

    authors： Ashby J,Foster C,Garvey L,Wan T,Allsop J,Paramesparan Y,Taylor-Robinson SD,Fidler S,Winston A

    更新日期：2015-03-01 00:00:00

  • HIV production from purified monocytes isolated from antiretroviral-naïve and protease inhibitor-treated HIV-1-infected patients.

    abstract：PURPOSE:We obtained peripheral blood monocytes from HIV-1-infected patients and differentiated them into macrophages in vitro to investigate the contribution of purified monocytes to plasma viremia in HIV-infected patients. METHOD:We compared the production of HIV-1 from purified monocytes isolated from patients who w...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/EF26-V3PC-AG5X-FCF4

    authors： Kazanjian P,Adams D,Tate S,Newman G

    更新日期：2002-11-01 00:00:00

  • Exercise training reduces oxidative stress in people living with HIV/AIDS: a pilot study.

    abstract：BACKGROUND:Exercise training has been shown to be an effective strategy to balance oxidative stress status; however, this is underexplored in people living with HIV/AIDS (PLWHA). OBJECTIVE:To evaluate the effects of exercise training on oxidative stress in PLWHA receiving antiretroviral therapy. METHODS:Patients perf...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,随机对照试验

    doi：10.1080/15284336.2018.1481247

    authors： Deresz LF,Schöler CM,de Bittencourt PIHJ,Karsten M,Ikeda MLR,Sonza A,Dal Lago P

    更新日期：2018-08-01 00:00:00

  • Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384.

    abstract：BACKGROUND:Effective and easy to implement interventions to improve adherence to antiretroviral therapy are needed. OBJECTIVE:To compare site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy to the study site's standard of care. METHODS:A rando...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,随机对照试验

    doi：10.1310/hct1405-235

    authors： Robbins GK,Testa MA,Su M,Safren SA,Morse G,Lammert S,Shafer RW,Reynolds NR,Chesney MA

    更新日期：2013-09-01 00:00:00

  • Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?

    abstract：PURPOSE:Proven clinical efficacy of protease-sparing regimens (PSR) has been shown. Concerns exist about broad applicability of these regimens in advanced naïve patients. Recent reports have associated a rise in liver enzymes with nevi rapine; however, no data exist with efavirenz. METHOD:17 consecutive antiretroviral...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/2V0B-HDWC-AGWR-H56M

    authors： Corales RB,Shrestha NK,Taege AJ,Isada CM,Rehm SJ,Schmitt SK,Gordon SM,Mawhorter SD

    更新日期：2001-01-01 00:00:00

  • Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.

    abstract：PURPOSE:A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of each boosted PI. METHODS:A c...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1103-133

    authors： Brogan AJ,Mrus J,Hill A,Sawyer AW,Smets E

    更新日期：2010-05-01 00:00:00

  • Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire.

    abstract：PURPOSE:Questionnaires assessing patient-reported outcomes in HIV are either too long or not HIV-specific. Our aim was to develop and validate a simplified HIV patient questionnaire. METHOD:607 HIV patients treated with a combination of antiretroviral (ARV) drugs were enrolled in an observational, longitudinal study. ...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/hct1004-215

    authors： Spire B,Arnould B,Barbier F,Durant J,Gilquin J,Landman R,Carret S,Saussier C,El Kebir S,Cohen-Codar I

    更新日期：2009-07-01 00:00:00

  • Clinically stable treatment-experienced adults receiving tenofovir and didanosine.

    abstract：METHOD:Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine. RESULTS:Patients trea...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/0B0R-J1LP-KQPF-43HB

    authors： Di Biagio A,Beltrame A,Cenderello G,Ferrea G,De Maria A

    更新日期：2006-01-01 00:00:00

  • Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.

    abstract：BACKGROUND:Raltegravir (RAL) constitutes the first available integrase strand transfer inhibitor (INSTI) available in clinical practice. Three independent pathways have been described to confer resistance to RAL. Secondary mutations with little effect on INSTI susceptibility and additional substitutions with an uncerta...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,多中心研究

    doi：10.1310/hct1401-10

    authors： Gutiérrez C,Hernández-Novoa B,Pérez-Elías MJ,Moreno AM,Holguín A,Dronda F,Casado JL,Moreno S

    更新日期：2013-01-01 00:00:00

  • Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes.

    abstract：BACKGROUND:Multiple resistance to nucleoside analogs mediated by the Q151M complex and/or codon 67-69 inserts/deletions represents a growing problem among HIV-infected persons, most of whom have been exposed to sequential therapies for long periods of time. PATIENTS AND METHOD:All plasma samples collected from HIV-inf...

    journal_title：HIV clinical trials

    pub_type： 杂志文章

    doi：10.1310/X618-KWKJ-WCTQ-LQ2L

    authors： Gallego O,d Mendoza C,Labarga P,Altisent C,González J,García-Alcalde I,Valer L,Valencia E,Soriano V

    更新日期：2003-11-01 00:00:00

  • Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.

    abstract：BACKGROUND:The success of longitudinal trials depends greatly on using effective strategies to retain participants and ensure internal validity, maintain sufficient statistical power, and provide for the generalizability of study results. OBJECTIVE:This paper describes the challenges and specific strategies used to re...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1080/15284336.2018.1513711

    authors： Wynne J,Muwawu R,Mubiru MC,Kamira B,Kemigisha D,Nakyanzi T,Kabwigu S,Nakabiito C,Kiweewa Matovu F

    更新日期：2018-10-01 00:00:00

  • Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening.

    abstract：BACKGROUND:In the HIV Prevention Trials Network (HPTN) 061 study, 8 (2.3%) of 348 HIV-infected participants identified as HIV uninfected at study enrollment using a single HIV rapid test for screening were found to be HIV infected after additional testing. OBJECTIVES:To evaluate the performance of different HIV assays...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/hct1502-62

    authors： Piwowar-Manning E,Fogel JM,Laeyendecker O,Wolf S,Cummings V,Marzinke MA,Clarke W,Breaud A,Wendel S,Wang L,Swanson P,Hackett J Jr,Mannheimer S,Del Rio C,Kuo I,Harawa NT,Koblin BA,Moore R,Blankson JN,Eshleman SH

    更新日期：2014-03-01 00:00:00

  • Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

    abstract：PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/HAG3-8YA5-UDQC-36NX

    authors： Smith GH,Boulassel MR,Klien M,Gilmore N,MacLeod J,LeBlanc R,René P,Routy JP,Lalonde RG

    更新日期：2005-03-01 00:00:00

  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDS.

    abstract：BACKGROUND:Impaired allostimulatory function of dendritic cells in patients with AIDS has been reported previously. Granulocyte-macrophage colony-stimulating factor (GM-CSF) can restore the T-cell stimulatory function in transforming growth factor-beta 1 (TGF-beta 1)-inhibited murine accessory cells. We now report the ...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/HP8B-NF27-VFWA-80YX

    authors： Bernstein ZP,Brooks SP,Chanan-Khan A,Gollnick SO,Gilbert MJ,Miller KC,Tomasi TB

    更新日期：2002-05-01 00:00:00

  • Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

    abstract：OBJECTIVE:To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-naïve subjects through 144 weeks. METHOD:This was a randomized, double-blind,...

    journal_title：HIV clinical trials

    pub_type： 杂志文章,随机对照试验

    doi：10.1310/hct1505-218

    authors： Kulkarni R,Abram ME,McColl DJ,Barnes T,Fordyce MW,Szwarcberg J,Cheng AK,Miller MD,White KL

    更新日期：2014-09-01 00:00:00

  • Monthly unannounced pill counts for monitoring HIV treatment adherence: tests for self-monitoring and reactivity effects.

    abstract：BACKGROUND:Unannounced home-based pill counts conducted in person or on the telephone are reliable and valid for monitoring medication adherence. However, expecting to have one's pills counted, organizing medications for pill counts, and increased attention from the person conducting the pill counts may have reactive e...

    journal_title：HIV clinical trials

    pub_type： 临床试验,杂志文章

    doi：10.1310/hct1106-325

    authors： Kalichman SC,Amaral C,Swetsze C,Eaton L,Kalichman MO,Cherry C,Detorio M,Caliendo AM,Schinazi RF

    更新日期：2010-11-01 00:00:00